The FDA's benefit-risk concerns on LOTIS-5 create a binary regulatory overhang for full approval of ZYNLONTA plus rituximab in 2L+ DLBCL. Watch for the company's regulatory strategy update and FDA engagement on the LOTIS-7 Phase 3 design, which could define the next catalyst path. The strong LOTIS-7 and MZL data support compendia and breakthrough designation submissions in 2027.
Drug in focus
ADCT drug pipeline →ZYNLONTA
◆ Mixed Named in this 8-K- Impact
- Phase
- Approved (accelerated approval); Phase 3 confirmatory (LOTIS-5) completed; Phase 1b combination (LOTIS-7) ongoing
- Time to market
- Already on the market (FDA accelerated approval April 2021). Path to full FDA approval is uncertain after LOTIS-5 safety issues. Japan decision timeline is not specified.
- Next catalyst
- None dated
What to watchWatch the 68th ASH Annual Meeting (December 5-8, 2026) where multiple ZYNLONTA abstracts will be presented, including updated LOTIS-7 combination data and potentially the full LOTIS-5 dataset. Also monitor the Japan marketing authorization decision by Tanabe Pharma (filed October 29, 2026) and any FDA guidance on the path to full approval. The stock trades near $1.51 with a 52-week range of $0.78-$4.98, reflecting deep uncertainty around the regulatory path.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 5 $1.64entry
- T+1 · 11d ago −3.66%α −3.97% · $1.58
- T+5 · 5d ago −14.02%α −17.32% · $1.41
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ADC Therapeutics announced positive clinical data from multiple ZYNLONTA trials to be presented at ASH 2026, including high response rates in LOTIS-7 (88.7% ORR) and MZL (93% ORR), alongside preliminary Q3 2026 net product revenue of $21M (up from $16M YoY) and a strengthened balance sheet following an $86.6M PIPE and debt refinancing. However, the LOTIS-5 confirmatory trial showed a Grade 5 safety imbalance (13.2% vs 4.6%) that the FDA flagged as a benefit-risk concern, creating regulatory uncertainty for full approval.
Key Financial Metrics
Key Facts
- Preliminary Q3 2026 ZYNLONTA net product revenue of $21M, up from $16M in Q3 2025
- LOTIS-7 Phase 1b: 88.7% ORR and 75.3% CR in 97 evaluable r/r DLBCL patients at 10.35 months median follow-up
- Phase 2 MZL IIT: 93% ORR and 74.4% CR in 43 evaluable patients with 90.8% two-year PFS
- LOTIS-5 Phase 3 met primary PFS endpoint (HR 0.73, p=0.0083) but Grade 5 TEAEs were 13.2% vs 4.6% in control arm
- FDA cited concerns regarding benefit-risk of ZYNLONTA plus rituximab from LOTIS-5; regulatory strategy update pending
- $86.6M PIPE closed October 22, 2026; HealthCare Royalty amendment removed $150M change-of-control payment
- Senior secured loan refinanced to $50M principal, bullet payment August 2029, no minimum liquidity covenant
- Pro forma cash of $196M post-refinancing; expected cash runway into 2029
- Cash and cash equivalents of $189.2M as of September 30, 2026
Financial Impact
Preliminary Q3 2026 net product revenue $21M (+31% YoY); pro forma cash $196M; $86.6M PIPE closed; debt principal reduced to $50M
Risk Factors
- FDA benefit-risk concerns on LOTIS-5 may delay or prevent full approval and sBLA submission
- Grade 5 safety imbalance (13.2% vs 4.6%) in LOTIS-5 could limit commercial adoption even if approved
- Dilution from $86.6M PIPE and warrant repricing (9.8M warrants reduced to $0.10 exercise price)
- Preliminary financials are subject to revision; actual Q3 results may differ
- Company is pre-revenue on an operating basis; relies on ZYNLONTA for all product revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000950103-26-016945 |
| Document: dp256258_ex9902.htm | 0000950103-26-016945 |
| Document: dp256258_8k.htm | 0000950103-26-016945 |
| Document: 0000950103-26-016945-index-headers.html | 0000950103-26-016945 |
| Document: 0000950103-26-016945-index.html | 0000950103-26-016945 |
| Document: 0000950103-26-016945.txt | 0000950103-26-016945 |
| 8-K Data (Synthetic) | 0000950103-26-016945 |
Track record
14 reports on ADCT
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $1.41 Now $1.25 −11.35% settles Dec 15
- Nov 9, 20267d ago S-3 Neutral 3/10 Entry $1.51 Now $1.25 −17.22% settles Dec 9
- Nov 9, 20267d ago 8-K Neutral 4/10 Entry $1.67 Now $1.25 −25.15% settles Dec 8
- Nov 4, 202612d ago 8-K Mixed 6/10 Viewing Entry $1.64 Now $1.25 −23.78% settles Dec 4
- Nov 3, 202613d ago S-4 Neutral 3/10 Entry $1.72 Now $1.25 −27.33% settles Dec 3
- Oct 29, 202618d ago SC 13G Neutral 4/10 Entry $1.53 Now $1.25 −18.30% settles Nov 30
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $1.70 to $1.51 Now $1.25 −26.47% ▼ −11.18% −7.57% vs SPY
- Aug 6, 202614w ago Press Release Neutral 1/10 Entry $1.13 to $1.32 Now $1.25 +10.62% ▲ +16.81% +16.21% vs SPY
- Jul 2, 202619w ago 8-K Neutral 2/10 Entry $1.19 to $1.11 Now $1.25 +5.04% ▼ −6.72% −6.31% vs SPY
- Jun 3, 202623w ago 8-K Mixed 6/10 Entry $1.32 to $1.19 Now $1.25 −5.30% ▼ −9.85% −8.48% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers